• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2021 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2021 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients

    Thumbnail
    URI
    https://rde.dspace-express.com/handle/11287/622175
    Author
    Simeng, Lin
    Nicholas, A. Kennedy
    Aamir, Saifuddin
    Diana Muñoz, Sandoval
    Catherine, Reynolds
    Rocio Castro, Seoane
    Sherine, Kottoor
    Franziska, Pieper
    Kai-Min, Lin
    David, K. Butler
    Neil, Chanchlani
    Rachel, Nice
    Desmond, Chee
    Claire, Bewshea
    Malik, Janjua
    Timothy, J. McDonald
    Shaji, Sebastian
    James, L. Alexander
    Laura, Constable
    James, C. Lee
    Charles, D. Murray
    Ailsa, L. Hart
    Peter, M. Irving
    Gareth-Rhys, Jones
    Klaartje, B. Kok
    Christopher, A. Lamb
    Charlie, W. Lees
    Daniel, M. Altmann
    Rosemary, J. Boyton
    James, R. Goodhand
    Nick, Powell
    Tariq, Ahmad
    Date
    2021-09-27
    Journal
    Research Square
    Type
    Journal Article
    Publisher
    Unknown
    DOI
    10.21203/rs.3.rs-755879/v1
    Rights
    © Research Square 2021
    Metadata
    Show full item record
    Abstract
    To inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2 vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell responses in patients treated with anti-tumour necrosis factor (anti-TNF), a commonly used biologic in inflammatory diseases, compared to patients treated with vedolizumab, a gut-specific antibody targeting integrin a4b7 that does not impair systemic immunity. In anti-TNF recipients, the magnitude of anti-SARS-CoV2 antibodies was reduced five-fold, and rapidly decayed towards the seroconversion threshold by 14 weeks after second dose of vaccine. In contrast, anti-SARS-CoV-2 antibodies were sustained up to 16 weeks in vedolizumab-treated patients. Anti-SARS-CoV2 antibody decay was not observed in vaccinated patients previously infected with SARS-CoV-2. T cell responses were absent in one-fifth of anti-TNF and vedolizumab-treated patients after a second dose of either vaccine. Our data have important implications for anti-TNF recipients, including the need for vaccine prioritization, booster doses, and social distancing strategies.
    Publisher URL
    https://www.scienceopen.com/document?vid=61332d7c-ef69-4193-a377-eb33c1bf23f4
    Note
    Not held
    Collections
    • 2021 RD&E publications
    • COVID-19
    • Gastroenterology

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2022  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV